Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1997 Dec 1;100(11):2824–2832. doi: 10.1172/JCI119830

Inhibition of rat vascular smooth muscle proliferation in vitro and in vivo by bone morphogenetic protein-2.

T Nakaoka 1, K Gonda 1, T Ogita 1, Y Otawara-Hamamoto 1, F Okabe 1, Y Kira 1, K Harii 1, K Miyazono 1, Y Takuwa 1, T Fujita 1
PMCID: PMC508488  PMID: 9389748

Abstract

Vascular proliferative disorders are characterized by the proliferation of vascular smooth muscle cells (SMCs) and excessive extracellular matrix synthesis. We found that bone morphogenetic protein-2 (BMP-2) inhibited serum-stimulated increases in DNA synthesis and cell number of cultured rat arterial SMCs in a fashion quite different from that in the case of transforming growth factor-beta1 (TGF-beta1). In addition, TGF-beta1 stimulated collagen synthesis in SMCs, whereas BMP-2 did not. In an in vivo rat carotid artery balloon injury model, the adenovirus-mediated transfer of the BMP-2 gene inhibited injury-induced intimal hyperplasia. These results indicate that BMP-2 has the ability to inhibit SMC proliferation without stimulating extracellular matrix synthesis, and suggest the possibility of therapeutic application of BMP-2 for the prevention of vascular proliferative disorders.

Full Text

The Full Text of this article is available as a PDF (630.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andrews P. W., Damjanov I., Berends J., Kumpf S., Zappavigna V., Mavilio F., Sampath K. Inhibition of proliferation and induction of differentiation of pluripotent human embryonal carcinoma cells by osteogenic protein-1 (or bone morphogenetic protein-7). Lab Invest. 1994 Aug;71(2):243–251. [PubMed] [Google Scholar]
  2. Battegay E. J., Raines E. W., Seifert R. A., Bowen-Pope D. F., Ross R. TGF-beta induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. Cell. 1990 Nov 2;63(3):515–524. doi: 10.1016/0092-8674(90)90448-n. [DOI] [PubMed] [Google Scholar]
  3. Boström K., Watson K. E., Horn S., Wortham C., Herman I. M., Demer L. L. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest. 1993 Apr;91(4):1800–1809. doi: 10.1172/JCI116391. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Brown G., Albers J. J., Fisher L. D., Schaefer S. M., Lin J. T., Kaplan C., Zhao X. Q., Bisson B. D., Fitzpatrick V. F., Dodge H. T. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990 Nov 8;323(19):1289–1298. doi: 10.1056/NEJM199011083231901. [DOI] [PubMed] [Google Scholar]
  5. Chamley-Campbell J., Campbell G. R., Ross R. The smooth muscle cell in culture. Physiol Rev. 1979 Jan;59(1):1–61. doi: 10.1152/physrev.1979.59.1.1. [DOI] [PubMed] [Google Scholar]
  6. Chang M. W., Barr E., Seltzer J., Jiang Y. Q., Nabel G. J., Nabel E. G., Parmacek M. S., Leiden J. M. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science. 1995 Jan 27;267(5197):518–522. doi: 10.1126/science.7824950. [DOI] [PubMed] [Google Scholar]
  7. Chang M. W., Ohno T., Gordon D., Lu M. M., Nabel G. J., Nabel E. G., Leiden J. M. Adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene inhibits vascular smooth muscle cell proliferation and neointima formation following balloon angioplasty of the rat carotid artery. Mol Med. 1995 Jan;1(2):172–181. [PMC free article] [PubMed] [Google Scholar]
  8. Chen J. K., Hoshi H., McKeehan W. L. Transforming growth factor type beta specifically stimulates synthesis of proteoglycan in human adult arterial smooth muscle cells. Proc Natl Acad Sci U S A. 1987 Aug;84(15):5287–5291. doi: 10.1073/pnas.84.15.5287. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Cunningham N. S., Paralkar V., Reddi A. H. Osteogenin and recombinant bone morphogenetic protein 2B are chemotactic for human monocytes and stimulate transforming growth factor beta 1 mRNA expression. Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):11740–11744. doi: 10.1073/pnas.89.24.11740. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Ferns G. A., Raines E. W., Sprugel K. H., Motani A. S., Reidy M. A., Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science. 1991 Sep 6;253(5024):1129–1132. doi: 10.1126/science.1653454. [DOI] [PubMed] [Google Scholar]
  11. Garg U. C., Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest. 1989 May;83(5):1774–1777. doi: 10.1172/JCI114081. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Grainger D. J., Kemp P. R., Witchell C. M., Weissberg P. L., Metcalfe J. C. Transforming growth factor beta decreases the rate of proliferation of rat vascular smooth muscle cells by extending the G2 phase of the cell cycle and delays the rise in cyclic AMP before entry into M phase. Biochem J. 1994 Apr 1;299(Pt 1):227–235. doi: 10.1042/bj2990227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Guzman R. J., Hirschowitz E. A., Brody S. L., Crystal R. G., Epstein S. E., Finkel T. In vivo suppression of injury-induced vascular smooth muscle cell accumulation using adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene. Proc Natl Acad Sci U S A. 1994 Oct 25;91(22):10732–10736. doi: 10.1073/pnas.91.22.10732. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Guzman R. J., Lemarchand P., Crystal R. G., Epstein S. E., Finkel T. Efficient and selective adenovirus-mediated gene transfer into vascular neointima. Circulation. 1993 Dec;88(6):2838–2848. doi: 10.1161/01.cir.88.6.2838. [DOI] [PubMed] [Google Scholar]
  15. Hansson G. K., Hellstrand M., Rymo L., Rubbia L., Gabbiani G. Interferon gamma inhibits both proliferation and expression of differentiation-specific alpha-smooth muscle actin in arterial smooth muscle cells. J Exp Med. 1989 Nov 1;170(5):1595–1608. doi: 10.1084/jem.170.5.1595. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hogan B. L. Bone morphogenetic proteins: multifunctional regulators of vertebrate development. Genes Dev. 1996 Jul 1;10(13):1580–1594. doi: 10.1101/gad.10.13.1580. [DOI] [PubMed] [Google Scholar]
  17. Indolfi C., Avvedimento E. V., Rapacciuolo A., Di Lorenzo E., Esposito G., Stabile E., Feliciello A., Mele E., Giuliano P., Condorelli G. Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo. Nat Med. 1995 Jun;1(6):541–545. doi: 10.1038/nm0695-541. [DOI] [PubMed] [Google Scholar]
  18. Israel D. I., Nove J., Kerns K. M., Moutsatsos I. K., Kaufman R. J. Expression and characterization of bone morphogenetic protein-2 in Chinese hamster ovary cells. Growth Factors. 1992;7(2):139–150. doi: 10.3109/08977199209046403. [DOI] [PubMed] [Google Scholar]
  19. Kanegae Y., Lee G., Sato Y., Tanaka M., Nakai M., Sakaki T., Sugano S., Saito I. Efficient gene activation in mammalian cells by using recombinant adenovirus expressing site-specific Cre recombinase. Nucleic Acids Res. 1995 Oct 11;23(19):3816–3821. doi: 10.1093/nar/23.19.3816. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Kanegae Y., Makimura M., Saito I. A simple and efficient method for purification of infectious recombinant adenovirus. Jpn J Med Sci Biol. 1994 Jun;47(3):157–166. doi: 10.7883/yoken1952.47.157. [DOI] [PubMed] [Google Scholar]
  21. Kojima I., Mogami H., Kawamura N., Yasuda H., Shibata H. Modulation of growth of vascular smooth muscle cells by activin A. Exp Cell Res. 1993 May;206(1):152–156. doi: 10.1006/excr.1993.1131. [DOI] [PubMed] [Google Scholar]
  22. Lawrence R., Hartmann D. J., Sonenshein G. E. Transforming growth factor beta 1 stimulates type V collagen expression in bovine vascular smooth muscle cells. J Biol Chem. 1994 Apr 1;269(13):9603–9609. [PubMed] [Google Scholar]
  23. Liu F., Hata A., Baker J. C., Doody J., Cárcamo J., Harland R. M., Massagué J. A human Mad protein acting as a BMP-regulated transcriptional activator. Nature. 1996 Jun 13;381(6583):620–623. doi: 10.1038/381620a0. [DOI] [PubMed] [Google Scholar]
  24. Majack R. A. Beta-type transforming growth factor specifies organizational behavior in vascular smooth muscle cell cultures. J Cell Biol. 1987 Jul;105(1):465–471. doi: 10.1083/jcb.105.1.465. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Majesky M. W., Lindner V., Twardzik D. R., Schwartz S. M., Reidy M. A. Production of transforming growth factor beta 1 during repair of arterial injury. J Clin Invest. 1991 Sep;88(3):904–910. doi: 10.1172/JCI115393. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Miyake S., Makimura M., Kanegae Y., Harada S., Sato Y., Takamori K., Tokuda C., Saito I. Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome. Proc Natl Acad Sci U S A. 1996 Feb 6;93(3):1320–1324. doi: 10.1073/pnas.93.3.1320. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Morisaki N., Kawano M., Koyama N., Koshikawa T., Umemiya K., Saito Y., Yoshida S. Effects of transforming growth factor-beta 1 on growth of aortic smooth muscle cells. Influences of interaction with growth factors, cell state, cell phenotype, and cell cycle. Atherosclerosis. 1991 Jun;88(2-3):227–234. doi: 10.1016/0021-9150(91)90085-h. [DOI] [PubMed] [Google Scholar]
  28. Nakamura T., Takio K., Eto Y., Shibai H., Titani K., Sugino H. Activin-binding protein from rat ovary is follistatin. Science. 1990 Feb 16;247(4944):836–838. doi: 10.1126/science.2106159. [DOI] [PubMed] [Google Scholar]
  29. Nikol S., Isner J. M., Pickering J. G., Kearney M., Leclerc G., Weir L. Expression of transforming growth factor-beta 1 is increased in human vascular restenosis lesions. J Clin Invest. 1992 Oct;90(4):1582–1592. doi: 10.1172/JCI116027. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Niwa H., Yamamura K., Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene. 1991 Dec 15;108(2):193–199. doi: 10.1016/0378-1119(91)90434-d. [DOI] [PubMed] [Google Scholar]
  31. Ohno T., Gordon D., San H., Pompili V. J., Imperiale M. J., Nabel G. J., Nabel E. G. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science. 1994 Aug 5;265(5173):781–784. doi: 10.1126/science.8047883. [DOI] [PubMed] [Google Scholar]
  32. Owens G. K., Geisterfer A. A., Yang Y. W., Komoriya A. Transforming growth factor-beta-induced growth inhibition and cellular hypertrophy in cultured vascular smooth muscle cells. J Cell Biol. 1988 Aug;107(2):771–780. doi: 10.1083/jcb.107.2.771. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Rade J. J., Schulick A. H., Virmani R., Dichek D. A. Local adenoviral-mediated expression of recombinant hirudin reduces neointima formation after arterial injury. Nat Med. 1996 Mar;2(3):293–298. doi: 10.1038/nm0396-293. [DOI] [PubMed] [Google Scholar]
  34. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993 Apr 29;362(6423):801–809. doi: 10.1038/362801a0. [DOI] [PubMed] [Google Scholar]
  35. Saito I., Oya Y., Yamamoto K., Yuasa T., Shimojo H. Construction of nondefective adenovirus type 5 bearing a 2.8-kilobase hepatitis B virus DNA near the right end of its genome. J Virol. 1985 Jun;54(3):711–719. doi: 10.1128/jvi.54.3.711-719.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Saltis J. TGF-beta: receptors and cell cycle arrest. Mol Cell Endocrinol. 1996 Feb 5;116(2):227–232. doi: 10.1016/0303-7207(95)03721-7. [DOI] [PubMed] [Google Scholar]
  37. Schluesener H. J., Meyermann R. Immunolocalization of BMP-6, a novel TGF-beta-related cytokine, in normal and atherosclerotic smooth muscle cells. Atherosclerosis. 1995 Mar;113(2):153–156. doi: 10.1016/0021-9150(94)05438-o. [DOI] [PubMed] [Google Scholar]
  38. Simons M., Edelman E. R., DeKeyser J. L., Langer R., Rosenberg R. D. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature. 1992 Sep 3;359(6390):67–70. doi: 10.1038/359067a0. [DOI] [PubMed] [Google Scholar]
  39. Takuwa Y., Ohse C., Wang E. A., Wozney J. M., Yamashita K. Bone morphogenetic protein-2 stimulates alkaline phosphatase activity and collagen synthesis in cultured osteoblastic cells, MC3T3-E1. Biochem Biophys Res Commun. 1991 Jan 15;174(1):96–101. doi: 10.1016/0006-291x(91)90490-x. [DOI] [PubMed] [Google Scholar]
  40. Wozney J. M., Rosen V., Celeste A. J., Mitsock L. M., Whitters M. J., Kriz R. W., Hewick R. M., Wang E. A. Novel regulators of bone formation: molecular clones and activities. Science. 1988 Dec 16;242(4885):1528–1534. doi: 10.1126/science.3201241. [DOI] [PubMed] [Google Scholar]
  41. Yamaguchi A., Katagiri T., Ikeda T., Wozney J. M., Rosen V., Wang E. A., Kahn A. J., Suda T., Yoshiki S. Recombinant human bone morphogenetic protein-2 stimulates osteoblastic maturation and inhibits myogenic differentiation in vitro. J Cell Biol. 1991 May;113(3):681–687. doi: 10.1083/jcb.113.3.681. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Yamashita H., ten Dijke P., Huylebroeck D., Sampath T. K., Andries M., Smith J. C., Heldin C. H., Miyazono K. Osteogenic protein-1 binds to activin type II receptors and induces certain activin-like effects. J Cell Biol. 1995 Jul;130(1):217–226. doi: 10.1083/jcb.130.1.217. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. ten Dijke P., Yamashita H., Sampath T. K., Reddi A. H., Estevez M., Riddle D. L., Ichijo H., Heldin C. H., Miyazono K. Identification of type I receptors for osteogenic protein-1 and bone morphogenetic protein-4. J Biol Chem. 1994 Jun 24;269(25):16985–16988. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES